We appreciate Aksu and colleagues for showing interest in our case in which we present cardioneuroablation as a treatment option to prevent ictal asystole.[@bib1]

In their comments they describe the approach of targeting low- and high-amplitude fractionated electrograms (LAFE and HAFE) in anatomical regions that are consistent with probable localization of ganglionated plexi.[@bib2]

Although some authors have tried to define procedural targets and endpoints of cardioneuroablation,[@bib3] they are not generally agreed upon; consequently, multiple different methods of achieving the same clinical endpoint are currently present.

In our case, the aim was to achieve sufficient vagal denervation to prevent heightened parasympathetic tone during focal epileptic seizure, which induced sinus arrest and syncope. To achieve this goal, we decided to target fractionated potentials in the anatomically defined areas. Furthermore, we decided to limit our ablation lesions only to the area around the interatrial septum and anteriorly of the right superior pulmonary vein and not to include the area around the left pulmonary veins. So far, after 10 months of follow-up, the patient has not experienced any syncope and no asystoles were recorded on the implantable loop recorder.

We are aware that our approach of partial or limited denervation may result in limited success rates, but we share adverse event concerns reported by other authors,[@bib4] as more aggressive strategies might carry excessive risks of proarrhythmia, esophageal thermal injury, or phrenic nerve paralysis.

In our opinion, until the cardioneuroablation method is tested in larger randomized studies and techniques are better defined, a less aggressive approach is warranted to avoid possible adverse events, even at the expense of an additional procedure.
